CBIO vs MRK
CBIO: A clinical-stage oncology biotech developing a PD-1 x VEGF bispecific antibody backbone and a portfolio of antibody-drug conjugates to treat solid tumors. MRK: Global pharmaceutical and vaccine leader with oncology, infectious disease, and animal health franchises, anchored by blockbuster immunotherapy Keytruda.
Side-by-side fundamentals
| Metric | CBIO | MRK | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $16.93 | $130.20 | |
| Market cap as of 2026-08-03 | $629M | $321.6B | |
| P/E as of 2026-08-03 | n/a | 36.63 | |
| PEG as of 2026-08-03 | n/a | 4.91 | |
| Net margin as of 2026-08-03 | -990.3% | +13.6% | MRK higher |
| Gross margin as of 2026-08-03 | -0.5% | +78.1% | MRK higher |
| Operating margin as of 2026-08-03 | -978.0% | +18.2% | MRK higher |
| ROE as of 2026-08-03 | -102.1% | +17.9% | MRK higher |
| ROA as of 2026-08-03 | -89.3% | +7.0% | MRK higher |
| Debt / equity as of 2026-08-03 | 0.00 | 1.07 | CBIO lower |
| Revenue growth (YoY) as of 2026-08-03 | +413.7% | +2.9% | CBIO higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +3.1% | |
| Dividend yield as of 2026-08-03 | n/a | +2.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-03 | 1.24 | 0.27 | |
| 1-year return as of 2026-07-27 close | +27.4% | +66.7% | MRK higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.